Tricuspid Regurgitation, the Once-Forgotten Valve: Current Management Options and Remaining Gaps After the 2025 European Society of Cardiology Guidelines Update
4 affiliations
- 1Division of Interventional Cardiology, Cardiovascular Department, “V. Fazzi” Hospital, 73100 Lecce, Italy
- 2Division of University Cardiology, “ICOT” Marco Pasquali Hospital, 04100 Latina, Italy
- 3Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy
- 4Division of University Cardiology, Cardiovascular and Thoracic Department, Policlinico University Hospital, 70124 Bari, Italy
Abstract
Historically considered a “neglected” valvular disease, moderate-to-severe tricuspid regurgitation (TR) is now recognized as an important contributor to morbidity, mortality, and right-sided heart failure (HF). Natural history studies show that significant TR is frequently associated with left-sided valve disease, particularly mitral valve disease, and independently predicts poor outcomes as severity increases. The 2025 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the Management of Valvular Heart Disease place unprecedented emphasis on TR, elevating this condition from a secondary afterthought to a central element of comprehensive valvular therapy. This reflects an evolution of evidence over the past decade, underscored by increased diagnostic sensitivity through multimodal imaging and the development of novel therapeutic options. However, gaps in the existing evidence persist, and addressing these uncertainties will support future research. This paper provides a comprehensive review of the evidence on TR, incorporates updates from the latest European guidelines, focuses on the most relevant and controversial aspects of patient selection, and identifies key areas where knowledge is insufficient. Furthermore, this review revisits the historical foundations of tricuspid valve research, highlighting how several anatomical concepts fundamental to contemporary interventions were already described as early as the 17th century, underscoring the long-standing scientific interest in this once “forgotten” valve.
Related
- 2025 European Society of Cardiology guidelines for the management of cardiovascular disease and pregnancy : Statement of endorsement by the NVVC.
- 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA): Developed by the task force on the management of cardiovascular disease and chronic kidney disease of the European Society of Cardiology (ESC)
- Robotic tricuspid valve repair for infective endocarditis with leaflet perforation and severe tricuspid regurgitation
- Phenotypes of Secondary Tricuspid Regurgitation
- Coexisting Moderate-to-Severe Tricuspid Regurgitation and Renal Dysfunction Identify a High-Risk Group After Transcatheter Aortic Valve Replacement
BibTeX
@article{cafaro2026tricuspid,
title = {{Tricuspid Regurgitation, the Once-Forgotten Valve: Current Management Options and Remaining Gaps After the 2025 European Society of Cardiology Guidelines Update}},
author = {Alessandro Cafaro and Amir Tahoun and Marco Mussardo and Alessandro Mandurino-Mirizzi and Luca Quarta and Francesco Rizzo and Antonio Tondo and Fortunato Iacovelli and Dionigi Fischetti and Giuseppe Colonna},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.31083/rcm53100},
url = {https://doi.org/10.31083/rcm53100},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Tricuspid Regurgitation, the Once-Forgotten Valve: Current Management Options and Remaining Gaps After the 2025 European Society of Cardiology Guidelines Update
AU - Alessandro Cafaro
AU - Amir Tahoun
AU - Marco Mussardo
AU - Alessandro Mandurino-Mirizzi
AU - Luca Quarta
AU - Francesco Rizzo
AU - Antonio Tondo
AU - Fortunato Iacovelli
AU - Dionigi Fischetti
AU - Giuseppe Colonna
PY - 2026
DA - 2026/10/16
JO - Reviews in Cardiovascular Medicine
DO - 10.31083/rcm53100
UR - https://doi.org/10.31083/rcm53100
AB - Historically considered a “neglected” valvular disease, moderate-to-severe tricuspid regurgitation (TR) is now recognized as an important contributor to morbidity, mortality, and right-sided heart failure (HF). Natural history studies show that significant TR is frequently associated with left-sided valve disease, particularly mitral valve disease, and independently predicts poor outcomes as severity increases. The 2025 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the Management of Valvular Heart Disease place unprecedented emphasis on TR, elevating this condition from a secondary afterthought to a central element of comprehensive valvular therapy. This reflects an evolution of evidence over the past decade, underscored by increased diagnostic sensitivity through multimodal imaging and the development of novel therapeutic options. However, gaps in the existing evidence persist, and addressing these uncertainties will support future research. This paper provides a comprehensive review of the evidence on TR, incorporates updates from the latest European guidelines, focuses on the most relevant and controversial aspects of patient selection, and identifies key areas where knowledge is insufficient. Furthermore, this review revisits the historical foundations of tricuspid valve research, highlighting how several anatomical concepts fundamental to contemporary interventions were already described as early as the 17th century, underscoring the long-standing scientific interest in this once “forgotten” valve.
SN - 1530-6550
SN - 2153-8174
ER -